about
Antipsychotic-induced sensitization and tolerance: Behavioral characteristics, developmental impacts, and neurobiological mechanismsCharacterization of schizophrenia adverse drug interactions through a network approach and drug classificationDrug treatment patterns in bipolar disorder: analysis of long-term self-reported data.Frequency and clinical relevance of potential cytochrome P450 drug interactions in a psychiatric patient population - an analysis based on German insurance claims data.To what extent are psychiatrists aware of the comorbid somatic illnesses of their patients with serious mental illnesses? - a cross-sectional secondary data analysisSelective serotonin reuptake inhibitor antidepressants potentiate methylphenidate (Ritalin)-induced gene regulation in the adolescent striatum.Age-related changes in antidepressant pharmacokinetics and potential drug-drug interactions: a comparison of evidence-based literature and package insert information.Attention-deficit-hyperactivity disorder: an update.Clinically significant psychotropic drug-drug interactions in the primary care setting.Common use of dietary supplements for bipolar disorder: a naturalistic, self-reported study.How the Probability and Potential Clinical Significance of Pharmacokinetically Mediated Drug-Drug Interactions Are Assessed in Drug Development: Desvenlafaxine as an Example.Drug-drug conditioning between citalopram and haloperidol or olanzapine in a conditioned avoidance response model: implications for polypharmacy in schizophreniaHistorical review of carbamazepine for the treatment of bipolar disorder.Monitoring of adverse drug reactions in psychiatry outpatient department of a Secondary Care Hospital of Ras Al Khaimah, UAE.The role of pharmacotherapy in the management of self-regulation difficulties in young childrenReversible dimers of the atypical antipsychotic quetiapine inhibit p-glycoprotein-mediated efflux in vitro with increased binding affinity and in situ at the blood-brain barrier.Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin-norepinephrine reuptake inhibitor.Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness.Psychotropic drug-drug interactions involving P-glycoprotein.Interactions between valproic acid and quetiapine/olanzapine in the treatment of bipolar disorder and the role of therapeutic drug monitoring.Retrospective use of PBPK modelling to understand a clinical drug-drug interaction between dextromethorphan and GSK1034702.Central Neuromodulators for Treating Functional GI Disorders: A Primer.Fluoxetine-induced toxicity results in human placental glutathione S-transferase-π (GST-π) dysfunction.Effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of clopidogrel in rats.An investigation of the behavioral mechanisms of antipsychotic action using a drug-drug conditioning paradigmElectronic database to detect drug-drug interactions between antidepressants and oral anticancer drugs from a cancer center in Singapore: implications to clinicians.Investigation of drug-drug interactions between clopidogrel and fluoxetine.Antidepressant and antipsychotic drugs differentially affect PON1 enzyme activity.Psychomotor and subjective effects of bilastine, hydroxyzine, and cetirizine, in combination with alcohol: a randomized, double-blind, crossover, and positive-controlled and placebo-controlled Phase I clinical trials.Psychiatric services: a platform for MTM.
P2860
Q26745506-D4D354C1-67FC-425B-804E-91F9C7463AF8Q28679280-EEB9375C-E26C-4828-BA4A-471AD042D8ABQ30878126-80DD04EA-0A09-4A41-B917-CC20D8268D5BQ31127895-EA1FB452-4E2A-44C7-AA32-CE3392B5A0C5Q31165280-F3ED1758-BAD1-441C-98D8-BFB4CB14EDD0Q34065820-EE4B5D04-2F00-4E72-96C4-219E4C748914Q34250313-3112E2D4-7D91-4CF5-AA3A-671C74F7C107Q34983475-886CE5A3-2174-474F-9C9D-CC7AC426EAE3Q35104220-F376DD86-FAF7-40F4-968B-7E0BEDD18666Q35671034-D84B0A46-14BA-4690-9B30-9A77BD84C135Q36028281-528C995B-5A66-42B2-943C-B54AE247A7BFQ36584779-B88E7976-38FC-40A5-A3C7-260315B0A243Q36693846-4E656B83-1FF2-4DEB-8881-859F6C75D60CQ37011680-B1C0DA0C-8A7C-4EE6-8078-B8B6B24F73E9Q37204884-7B120367-A9B8-4051-9B13-698C10679210Q37709400-9D8EF5F9-45C9-4B06-9726-1BAD855D9086Q37808483-7CA4BE03-4103-4B51-A97B-C3197EE632E0Q37961830-02C99B4B-4D6F-42E5-971B-5E7DCE164D8EQ38047816-15A0AE40-DE1C-44BC-93C6-ACC67B32F5F2Q38176041-8D915BA1-774C-48A6-A58A-55BA20F9E376Q39136867-A5D9F9D5-FE23-478F-8B76-13F9070B7A55Q39204575-F99742D4-A248-4904-ADC3-D5155596BB71Q40000787-3B406947-D21C-4F2C-B484-BFCC80BE7223Q40842333-984146E0-561E-4DE6-A6F3-298B3EBE7420Q41890120-9D238FD9-CCF9-47F0-BE97-A29F8CDA916AQ44022495-689D7DF6-97E6-4209-8BC4-37276C79BA8DQ45332852-4B044C9C-6C86-4F0A-BAB9-591CD6AEEF5DQ47857122-784C6F1F-3023-44A8-8B0B-E66321476A59Q47933632-DBFDAB68-4DC5-4937-8A84-9DF1DAF2A558Q50602348-D43590CC-4D75-4962-8642-FF1A555CDAD1
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականին հրատարակուած գիտական յօդուած
@hyw
2005 թվականին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
An overview of psychotropic drug-drug interactions
@ast
An overview of psychotropic drug-drug interactions
@en
An overview of psychotropic drug-drug interactions
@nl
type
label
An overview of psychotropic drug-drug interactions
@ast
An overview of psychotropic drug-drug interactions
@en
An overview of psychotropic drug-drug interactions
@nl
prefLabel
An overview of psychotropic drug-drug interactions
@ast
An overview of psychotropic drug-drug interactions
@en
An overview of psychotropic drug-drug interactions
@nl
P2093
P3181
P1433
P1476
An overview of psychotropic drug-drug interactions
@en
P2093
Kelly L Cozza
Neil B Sandson
Scott C Armstrong
P304
P3181
P356
10.1176/APPI.PSY.46.5.464
P407
P577
2005-01-01T00:00:00Z